Compare Equinor ASA (EQNR) vs Sanofi SA (SNY) Price & Performance

EQNR trades at $42.93, up 3.17% today, with a bullish technical outlook supported by moving averages. The stock shows attractive valuation metrics including a P/E of 11.63 and EV/EBITDA of 2.39, while maintaining strong profitability with 21.32% ROE. Recent earnings beat expectations in two of the last three quarters, and the company continues expanding its LNG portfolio with new Asian supply agreements.

EQNR presents compelling value with significant upside to the $87.50 consensus price target. However, declining revenue and net income margins since 2022, coupled with negative net cash flow trends, warrant caution. The stock's performance remains sensitive to energy market volatility and execution of LNG expansion plans through the early 2030s.

Sanofi (SNY) trades at $40.23, showing minimal daily movement with a 0.07% gain. The stock presents mixed signals with bearish technical indicators but strong fundamental performance, including three consecutive quarterly earnings beats. Recent expansion of the immunology alliance with Regeneron through an $8 billion deal highlights strategic growth initiatives. Valuation metrics show a P/E of 22.14 and P/S of 1.77, while profitability remains solid with a 72.77% gross margin.

SNY offers steady growth potential driven by pipeline expansion and Dupixent momentum, though patent expiration risks loom. Analyst sentiment is cautiously optimistic with 44% buy ratings, but technical weakness and projected 2026 earnings decline present near-term headwinds. The stock represents a balanced opportunity for long-term investors seeking pharmaceutical exposure with manageable risk.